Pharvaris (NASDAQ:PHVS) Shares Sold by Pictet Asset Management SA

Posted by on Feb 26th, 2023

Pictet Asset Management SA lowered its stake in shares of Pharvaris (NASDAQ:PHVS – Get Rating) by 13.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 399,875 shares of the company’s stock after selling 62,755 shares during the quarter. Pictet Asset Management SA owned approximately 1.26% of Pharvaris worth $3,211,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its stake in Pharvaris by 2.0% during the second quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company’s stock worth $1,259,000 after purchasing an additional 1,115 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Pharvaris during the third quarter valued at about $26,000. Finally, Bank of America Corp DE grew its holdings in Pharvaris by 1,054.4% during the first quarter. Bank of America Corp DE now owns 5,772 shares of the company’s stock worth $105,000 after acquiring an additional 5,272 shares during the period. 70.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PHVS shares. JMP Securities lifted their target price on Pharvaris from $22.00 to $23.00 and gave the stock a “market outperform” rating in a report on Wednesday, January 11th. SVB Leerink decreased their price objective on Pharvaris from $20.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, February 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $7.85 on Friday. The stock has a market capitalization of $275.41 million, a price-to-earnings ratio of -4.73 and a beta of -4.78. The business’s fifty day moving average price is $9.67 and its two-hundred day moving average price is $8.01. Pharvaris has a fifty-two week low of $1.77 and a fifty-two week high of $27.50.

Pharvaris (NASDAQ:PHVS – Get Rating) last issued its quarterly earnings results on Thursday, December 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.39. Research analysts expect that Pharvaris will post -2.03 EPS for the current fiscal year.

Pharvaris Company Profile

(Get Rating)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).

Featured Stories

Institutional Ownership by Quarter for Pharvaris (NASDAQ:PHVS)

Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.